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Abstract
 
PGD
 
2
 
, a lipid mediator released from mast cells, is known to participate in allergic reactions.
However, the mechanism by which PGD
 
2
 
 contributes to such reactions remains unclear. We
established a novel experimental model of asthma that permitted direct assessment of the role of
PGD
 
2
 
 in airway inflammation. Antigen-sensitized mice were exposed to aerosolized prosta-
glandin D
 
2
 
 (PGD
 
2
 
) 1 d before challenge with low-dose aerosolized antigen. Not only the
numbers of eosinophils, lymphocytes, and macrophages but also the levels of IL-4 and IL-5 in
bronchoalveolar lavage fluid were higher in PGD
 
2
 
-pretreated mice than in control mice. The
expression of macrophage-derived chemokine (MDC), a chemoattractant for Th2 cells, was
greater in PGD
 
2
 
-pretreated mice than in control. Injection of anti-MDC antibody into
PGD
 
2
 
-pretreated mice markedly inhibited inflammatory cell infiltration as well as Th2 cyto-
kine production after antigen challenge. These results indicate that PGD
 
2
 
 accelerates Th2 type
inflammation by induction of MDC. Our results suggest that this mechanism may play a key
role in the development of human asthma and that MDC might be a target molecule for ther-
apeutic intervention.
Key words: bronchial asthma • chemokines • epithelial cells • prostanoids • Th2 cells
 
Introduction
 
Th2 cells play a critical role in the pathogenesis of bron-
chial asthma (1–4). Th2 cells produce cytokines such as
IL-4, -5, -9, and -13, which induce IgE production as well
as mast cell and eosinophil activation (5, 6). Recent analy-
ses of mice lacking T1/ST2, a Th2-specific cell surface
molecule, and those lacking signal transducer and activator
of transcription–6, strongly support important roles of Th2
cells and the cytokines they secrete in the development of
bronchial asthma (7, 8). Th2 cells are recruited into the air-
way mucosa (9–13) and are found in the bronchoalveolar
lavage (BAL) fluid of patients with asthma (14–20).
Over the past few years, the ability of chemokines (che-
motactic cytokines) to attract inflammatory cells to the lung
in patients with asthma has received considerable attention.
Recent papers suggest that bronchial epithelial cells may
directly perpetuate Th2 type airway inflammation by
producing certain chemokines, such as thymus- and acti-
vation-regulated chemokine (TARC) and macrophage-
derived chemokine (MDC; references 21–23). These two
chemokines, ligands for CC chemokine receptors (CCRs;
reference 24) 4, are potent chemoattractants for Th2 cells
(25–27) and have been implicated in Th2 type inflamma-
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Abbreviations used in this paper:
 
 AHR, airway hyperresponsiveness; BAL,
bronchoalveolar lavage; BMMC, bone marrow mast cell; CCR, CC che-
mokine receptor; MCP, monocyte chemotactic protein; MDC, macro-
phage-derived chemokine; PGD
 
2
 
, prostaglandin D
 
2
 
; RANTES, regulated
upon activation normal T cell expressed and secreted; RT, reverse tran-
scriptase; TARC, thymus- and activation-regulated chemokine.T
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tion associated with the development of airway hyperre-
sponsiveness (AHR; references 28–30). We have reported
previously that IL-9, a Th2 type cytokine, is essentially in-
volved in Th2 type pulmonary inflammation associated
with AHR in a murine model of asthma, possibly via in-
duction of MDC in bronchial epithelial cells (31). These
results suggested that once Th2 cells are recruited into the
lung, Th2 type inflammation might be exaggerated via the
IL-9–MDC loop. Thus, identification of factors that ini-
tially induce MDC is critical to understanding the mecha-
nism initiating Th2 type pulmonary inflammation.
Mast cells also have an important part in asthma. Acti-
vated mast cells contribute to asthmatic pulmonary inflam-
mation by producing a variety of chemical mediators and
cytokines. Prostaglandin D
 
2
 
 (PGD
 
2
 
), the major cyclooxy-
genase metabolite of arachidonic acid (32–34), is one
chemical mediator released in large amounts by mast cells
during asthmatic attacks in humans. PGD
 
2
 
 has been pro-
posed as a marker of mast cell activation in asthma (35, 36).
Recent papers have shown that mice lacking G protein–
coupled receptors were resistant to experimentally induced
allergic asthma, suggesting that PGD
 
2
 
 mediated by PGD
receptors participates in the development of allergic asthma
(37). Furthermore, Fujitani et al. reported recently that the
levels of Th2 cytokines are elevated, accompanied by in-
creased accumulation of eosinophils and lymphocytes, in
the lungs of prostaglandin D synthase transgenic mice (38).
These works suggested that PGD
 
2
 
 is involved in Th2 type
pulmonary inflammation characterized by recruitment of
eosinophils and Th2 cells. However, the mechanism by
which PGD
 
2
 
 functions remains unclear.
We have developed a novel model of inducible allergic
asthma by carefully titrating the dose of antigen. This
model enabled us to directly assess the effect of inhaled
PGD
 
2
 
. Using this model, we show here that PGD
 
2
 
 in-
creased the recruitment of eosinophils and CD4
 
 
 
 T cells,
especially Th2 cells, into the lung. We also found that PGD
 
2
 
exerts its asthma-promoting activity via induction of MDC in
pulmonary epithelial cells. Our results provide evidence that
PGD
 
2
 
 acts via MDC, thought to function as a molecular
link between PGD
 
2
 
 and Th2 type inflammation in asthma.
 
Materials and Methods
 
Animals. 
 
Specific pathogen-free male BALB/c mice (6–8-
wk-old; Japan SLC Inc.) were used in all experiments. The study
protocol was reviewed and approved by the Dokkyo University
School of Medicine Committee on Animal Care and complies
with National Institutes of Health guidelines for animal care.
 
Sensitization and Antigen Challenge of Mice. 
 
To investigate the
roles of PGD
 
2
 
 in the development of Th2 type response, we ana-
lyzed pulmonary inflammation in mice sensitized and challenged
with low doses of antigen. In preliminary studies, we determined
the degree of antigen exposure that induced marginal pulmonary
responses and inflammation, as compared with established murine
models of asthma (Fig. 1, method 1). First, BALB/c mice were
sensitized and challenged with antigen according to a conven-
tional protocol (31, 39). In brief, mice were sensitized on days 0
and 5 by i.p. injections of OVA (Sigma-Aldrich) (8 
 
 
 
g/mouse)
adsorbed on aluminum hydroxide (Wako Pure Chemical Indus-
tries). To induce experimental asthma, the sensitized mice were
challenged with aerosolized 1% OVA (two 60-min sessions sepa-
rated by an interval of 4 h) on day 17. Second, to evaluate the ef-
fects of PGD
 
2
 
 (Fig. 1, method 2), sensitized mice were exposed
to aerosolized PGD
 
2
 
 (10
 
 
 
3
 
 M) or saline on day 16, followed by
one provocation with aerosolized 0.1% OVA for 30 min on day
17 (a low-dose antigen asthma model). In preliminary studies, we
determined the amount of PGD
 
2
 
 that induced no obvious histo-
logical changes, such as inflammatory cell recruitment and tissue
edema. Each mouse was killed at the indicated times before or af-
ter challenge (Fig. 1).
 
BAL. 
 
BAL was performed immediately before and 3 and 24 h
after the last aerosol challenge. At the time of lavage, the mice
were killed with an overdose of 100 mg/kg body weight of so-
Figure 1. Protocols used in this work. Method (1),
conventional standard asthma model; method (2),
newly established asthma model for analysis of effects in
PGD2-pretreated mice; and method (3), analysis of ef-
fects of anti-MDC antibody ( MDC) on PGD2-pro-
moted Th2 type inflammation and AHR. *, Analysis of
cytokines, cell populations, and histological findings
before 0, 3, or 24 h after OVA challenge.T
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dium pentobarbitone (pentobarbital sodium). The trachea was
exposed and cannulated with polyethylene tubing. The lungs
were lavaged with three 0.5-ml aliquots of saline. The superna-
tant was stored at 
 
 
 
70
 
 
 
C.
Total cell numbers were counted with a hemocytometer.
Cytospin preparations of BAL cells were stained with Diff-Quik
solution (Dade Behring Inc.) to determine the differential cell
count, evaluated on the basis of at least 500 leukocytes.
 
Histological Examination of Lung. 
 
The lungs were taken from
the mice, fixed in neutralized buffered formalin, and embedded
in paraffin. Sections 3-
 
 
 
m thick were stained with Luna solution
for eosinophils and toluidine blue for mast cells.
 
OVA-specific T Cell and Bone Marrow Mast Cell (BMMC) Re-
sponse In Vitro. 
 
10 d after intraperitoneal immunization with
OVA as described above in the 
 
Sensitization and Antigen Challenge
of Mice
 
 section, mice spleen cells were isolated and cultured with
10
 
 
 
9
 
–10
 
 
 
5
 
 M PGD
 
2
 
 during stimulation with 10 
 
 
 
g/ml OVA for
24 h (31, 40). For BMMC culture, intact femurs and tibias were
removed from mice, and bone marrow cells were harvested by
repeated flushing with MEM. A cell culture was established at a
density of 3 
 
 
 
 10
 
6
 
 cells/ml in IMDM, supplemented with 10%
FCS (inactivated at 56
 
 
 
C), 2 mM 
 
l
 
-glutamine, 1 mM pyruvate,
100 U/ml penicillin, 100 mg/ml streptomycin, 20 U/ml mIL-3,
and 50 U/ml mIL-4. Nonadherent cells were transferred to fresh
culture plates every 2–3 d for a total of at least 21 d to remove ad-
herent macrophages and fibroblasts (31, 41). Toluidine blue stain-
ing revealed that the resulting cell population consisted of 
 
 
 
99%
BMMCs. These cells were cultured with 0.25 
 
 
 
M ionomycin
during stimulation with 10
 
 
 
9
 
–10
 
 
 
5
 
 M PGD
 
2
 
.
 
Detection of Pulmonary T1/ST2
 
 
 
 T Cells. 
 
To examine the ac-
cumulation of Th2 cells in the lungs, we analyzed the expres-
sion of T1/ST2, a Th2 surface marker, on intrapulmonary CD3
 
 
 
cells obtained from the PGD
 
2
 
-treated sensitized animals at the in-
dicated times before and after challenge (Fig. 1, method 2). Lungs
were perfused with PBS without magnesium or calcium to mini-
mize contamination of the final lung cell population by cells from
blood. The tissues were suspended in RPMI 1640 (HyClone
Laboratories) medium containing 1 mg/ml type II collagenase
(Worthington Biochemical Corp.) and incubated at 37
 
 
 
C for 30
min to permit digestion. The tissues were pressed through a 70-
 
 
 
m cell strainer (Becton Dickinson). Total lung cells were sus-
pended in 40% isotonic Percoll solution (Amersham Biosciences),
pelleted by centrifugation at 900 
 
g
 
 for 20 min, and washed in the
medium after hemolysis of the cells by suspension in lysing buffer
(ACK; BioWhittaker Inc.). Cells gathered from the BLA fluid of
five mice were used for analysis for each experimental condition
because the absolute cell number per mouse was extremely small.
The lung cells and BAL fluid cells were stained with CD3 and
T1/ST2 and analyzed by flow cytometry. Phenotypic analysis of
lung cells was performed with the use of PE-conjugated anti-
CD3 (clone 145–2C11) and FITC-conjugated anti–mouse T1/
ST2 (clone 3E10; Millennium Pharmaceuticals Inc.). All antibod-
ies, except anti-T1/ST2, were purchased from BD Biosciences.
As a control, cells incubated with an isotype-matched, directly
conjugated antibody with irrelevant specificity were used. After
incubation for 30 min at 4
 
 
 
C, the cells were washed, and immu-
nofluorescence analysis was performed on a FACSCalibur™ flow
cytometer (Becton Dickinson). The results were analyzed with
CELLQuest™ software (Becton Dickinson).
 
Immunocytochemistry. 
 
Paraffin sections of lung tissue were de-
paraffinized and hydrated by submersion in xylene followed by
reagent-grade alcohol. The sections were rinsed for 5 min and in-
cubated with 0.3% H
 
2
 
O
 
2
 
 for 30 min to quench endogenous per-
oxidase activity. After washing three times in Trizma buffer solu-
tion for 15 min, the sections were incubated with goat-anti–
mouse MDC or TARC antibody or an isotype control antibody
overnight. Next, the sections were washed three times in Trizma
buffer solution for 15 min, and a rabbit anti–goat IgG secondary
antibody was applied for 30 min. After washing, the sections were
incubated with streptavidin peroxidase reagent for 30 min. The
sections were washed again and stained with peroxidase substrate
solution until the desired intensity was reached. After rinsing in
running water, the sections were counterstained with hematoxy-
lin. The used reagents were derived from commercially available
streptavidin-biotin kits (DakoCytomation).
 
Culture of Primary Human Bronchial Epithelial Cells. 
 
In these
studies, we used primary human bronchial epithelial cells (Nor-
mal Human Cell System; Sanko Junyaku). Cells were main-
tained in bronchial epithelial growth media (SABM; Sanko Jun-
yaku) and supplemented with 7.5 g/liter of bovine pituitary
extract, 0.5 g/liter hydrocortisone, 0.5 mg/l of human recombi-
nant epidermal growth factor, 0.5 g/liter epinephrine, 10 g/liter
transferrin, 5 g/liter insulin, 0.1 mg/l retinoic acid, 6.5 mg/l
3,3
 
 
 
,5-triiodo-
 
l
 
-thryonine, 50 g/liter bovine serum albumin,
and 0.1% GA-1000 (Sanko Junyaku) in 25-cm
 
2
 
 tissue plates at
37
 
 
 
C in 5% CO
 
2
 
. Media were replaced every other day. Cells
reached confluency in 9–9.5 d, and nearly confluent cells were
subcultured using trypsin-EDTA at a ratio of 1:8 at passage 3 for
experimental treatment.
 
Preparation of mRNA and Reverse Transcriptase (RT)–PCR.
 
Total RNA was extracted from the primary human bronchial
epithelial cells by Trisolv, a modified guanidine thiocyanate-
phenol-chloroform method, as recommended by the manufac-
turer (Biotec Laboratories). RT-PCR was performed to deter-
mine the relative quantities of TARC and MDC mRNA, using
a modified method as described previously (42). In brief, 1 
 
 
 
g
RNA was reverse-transcribed using oligo (dT) primers; the
cDNA underwent 30, 30, or 22 cycles of amplification with
primers specific for TARC, MDC, and 
 
 
 
-actin. The sequences
of primers from the coding regions of human genes were as fol-
lows: MDC, 5
 
 
 
-TACAGACTGCACTCCTGGTTGTCC-3
 
 
 
and 5
 
 
 
-TTCTGGCGGGGAGCAGCTATAATG-3
 
 
 
; TARC,
5
 
 
 
-CACGCAGCTCGAGGGACCAATGTG-3
 
 
 
 and 5
 
 
 
-TCA-
AGACCTCTCAAGGCTTTGCAGG-3
 
 
 
; 
 
 
 
-actin, 5
 
 
 
-TGAC-
GGGGTCACCCACACTGTGCCCATCTA-3
 
 
 
 and 5
 
 
 
-CTA-
GAAGCATTGCGGTGGACGATGGAGGG-3
 
 
 
. PCR products
in agarose gel were detected by ethidium bromide staining.
 
Stimulation of Primary Human Bronchial Epithelial Cells with
PGD
 
2
 
. 
 
To assess the effects of PGD
 
2
 
 on MDC and TARC
gene expression, primary human bronchial epithelial cells were
stimulated with various concentrations of PGD
 
2
 
 (10
 
 
 
9
 
–10
 
 
 
5
 
 M).
Cultures were harvested after stimulation for 48 h and analyzed
by RT-PCR.
 
Effect of Anti-MDC Antibody on PGD
 
2
 
-mediated Pulmonary Re-
sponse. 
 
For blocking experiments, intraperitoneally sensitized
PGD
 
2
 
- or saline-treated mice were given 20 
 
 
 
g/mouse of neu-
tralizing rabbit polyclonal antibody against murine MDC (anti-
MDC antibody; R&D Systems). This antibody was administered
i.v. 30 min before OVA challenge or saline. As control, OVA-
challenged mice were given the same amount of rabbit Ig control
Ig-G (DakoCytomation) by i.v. injection (Fig. 1, method 3). In
these mice, AHR was assessed 24 h after challenge.
 
Determination of AHR after Allergen Challenge. 
 
AHR to in-
haled methacholine in conscious, spontaneously breathing mice
was measured by barometric whole body plethysmography (Buxco
Electronics) as described previously (31, 43–45). Mice wereT
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placed in the main chamber, and baseline readings were obtained
and averaged for 3 min. Saline or increasing concentrations of
3–25 mg/ml methacholine was aerosolized through an inlet of
the main chamber for 3 min, and readings were taken and aver-
aged for 3 min after each challenge. Airway reactivity was ex-
pressed as enhanced pause (Penh) values for each concentration of
methacholine.
Measurement of Cytokines and Chemokines.  Concentrations of
cytokines (IL-2, IL-4, IL-5, IL-13, and IFN- ) and chemokines
(regulated upon activation normal T cell expressed and secreted
[RANTES], eotaxin, and monocyte chemotactic protein [MCP]–1)
in culture supernatants and BAL fluid supernatants were measured
by ELISA kits (R&D Systems) according to the manufacturer’s
instructions.
Statistical Analysis.  Data are expressed as means   SEM. The
statistical significance of differences between groups was assessed
by analysis of variance. P values of  0.05 were considered to in-
dicate statistical significance.
Results
Description of the Model System.  Compared with the an-
tigen doses usually used for challenge (31, 39), much
smaller amounts of OVA were given to BALB/c mice to
determine the antigen challenge required to optimally high-
light the effect of PGD2 inhalation on pulmonary inflam-
mation (Fig. 1, method 1). In preliminary studies, we found
that 0.1% OVA inhalation for 30 min, instead of two
rounds of inhalation of 1% OVA for 60 min (as used in
conventional protocols), induced only marginal inflamma-
tion in the lung (unpublished data). We also confirmed that
total cell numbers and cell populations in BAL fluid of sen-
sitized mice were not altered 24 h after provocation with
PGD2 alone (Fig. 2 A, 0 h) when no challenging antigens
were given. This finding indicated that PGD2 alone had no
chemoattractive effect in the lung. In contrast, 3 h after
low-dose antigen (0.1% OVA) inhalation, total cell num-
bers in BAL fluid were significantly higher in PGD2-pre-
treated mice than in saline-pretreated control mice (Fig. 2
A). The infiltrated cells consisted predominantly of eosino-
phils, lymphocytes, and macrophages, with few neutrophils.
Further increases in each cell type were seen 24 h after low-
dose antigen challenge, as compared with the control (Fig.
2 B). The numbers of eosinophils and lymphocytes in BAL
fluid did not differ significantly between the conventional
asthma model challenged with 1% OVA and the PGD2-
pretreated mice challenged with 0.1% OVA 24 h after anti-
gen challenge. In contrast, the number of macrophages in
the conventional asthma model was significantly greater
than that in the PGD2-pretreated mice (Fig. 2 B). The re-
sults of histological examinations were consistent with the
findings in BAL fluid (unpublished data). These data sug-
gested that pretreatment with PGD2 augmented low-dose
antigen-induced Th2 type pulmonary inflammation involv-
ing mainly eosinophils and lymphocytes.
Effect of PGD2 on Cytokine and Chemokine Concentrations
in BAL Fluid.  First, the expression of the chemokines
eotaxin, RANTES, and MCP-1 were measured in BAL
fluid obtained from sensitized animals after OVA challenge
(Fig. 1, methods 1 and 2). None of these chemokines were
detected immediately before or 3 h after OVA challenge in
either PGD2-pretreated animals or in conventional asthma
models (unpublished data). Although increased levels of all
three chemokines were found in conventional asthma
models 24 h after 1% OVA challenge, only eotaxin was in-
creased by low-dose OVA (0.1%) challenge to a level simi-
lar to that in conventional asthma models (Fig. 3). We also
analyzed Th1 (IL-2 and IFN- ) and Th2 (IL-4 and IL-5)
cytokines in BAL fluid. No Th1 cytokines were detected
in any model, consistent with the exclusively Th2-depen-
dent nature of these models. Moreover, there was no sig-
nificant difference in the levels of Th2 cytokines in BAL
fluid 24 h (Fig. 4 A, 0 h before OVA challenge) after PGD2
pretreatment. This result indicated that PGD2 alone had no
significant effect on the induction of Th2 cytokines or on
cell infiltration in the lung. Notably, 3 h after low-dose an-
Figure 2. Effects of PGD2 on infiltration of inflammatory cells in BAL
fluid. The number of inflammatory cells in BAL fluid was determined 0,
3 (A), and 24 h (B) after the last challenge on experimental day 17, as de-
scribed in Materials and Methods. Data represent means   SEM per
group (n   6). Differences were considered significant if P   0.05. (A) *,
P   0.05, between PGD2-pretreated low-dose 0.1% OVA-challenged
groups (black bars) and saline-pretreated, low-dose OVA-challenged
groupsgroups (white bars). (B) *, P   0.05, between PGD2-pretreated,
low-dose 0.1% OVA-challenged groups (black bars) and saline-pre-
treated, low-dose OVA-challenged groups (white bars). Gray bars repre-
sent data obtained with the conventional asthma model. Groups of mice
pretreated with PGD2 but challenged with saline are represented by diag-
onally striped bars. N.S., not significant; N.D., not detected.T
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tigen (0.1% OVA) inhalation, Th2 cytokine levels were
significantly higher in PGD2-pretreated mice than in the
saline-pretreated control mice (Fig. 4 A). IL-5 levels were
elevated similarly in PGD2-treated mice and in conven-
tional asthma models 24 h after OVA challenge, whereas
the IL-4 level was slightly lower in the former (Fig. 4 B).
The levels of Th2 cytokines increased 24 h after challenge,
as compared with those 3 h after challenge; no such in-
crease was observed in saline-treated animals (Fig. 4 B).
These results suggested that PGD2 pretreatment could lead
to intrapulmonary accumulation of Th2 cytokines in sensi-
tized animals exposed to low-dose antigen.
Effects of PGD2 on Cytokine Production by OVA-specific T
Cells and BMMCs In Vitro.  To determine whether PGD2
stimulation directly influences Th2 cytokine production,
we analyzed ovalbumin-specific T cell response in vitro.
Addition of PGD2 did not affect ovalbumin-induced Th2
cytokine production by spleen T cells (Fig. 5). In addition,
PGD2 did not affect ionomycin-induced Th2 cytokine
production by bone marrow–derived mast cells (unpub-
lished data). These results indicate that PGD2 does not di-
rectly up-regulate the production of Th2 cytokines and
suggest that PGD2 is involved in the recruitment of acti-
vated Th2 cells into the lung after antigen exposure.
Effects of PGD2 on the Expression of MDC mRNA and Pro-
tein In Vivo and In Vitro.  Next, we examined the role of
MDC or TARC in Th2 cell recruitment into the lung in
terms of the action of PGD2. First, we observed that MDC
mRNA was expressed in primary human bronchial epithe-
lial cells in a dose-dependent manner in response to 10 9–
10 5 M PGD2 after a 48-h incubation (Fig. 6). In contrast,
TARC mRNA was constitutively expressed and not influ-
enced by PGD2. We analyzed MDC expression immuno-
histochemically 3 and 24 h after OVA challenge in our
murine asthma model (Fig. 1, method 2). The PGD2-pre-
Figure 3. Effects of PGD2 on chemokine concentrations in BAL fluid.
RANTES, eotaxin, and MCP-1 concentrations in BAL fluid were as-
sessed 24 h after the last challenge. Gray and black bars represent the con-
ventional asthma model groups and the PGD2-pretreated, low-dose
OVA-challenged groups, respectively. Data are expressed as means  
SEM per group (n   6). *, Significant differences (P   0.05) between
PGD2-pretreated, low-dose OVA-challenged groups (black bars) and sa-
line-pretreated, low-dose OVA-challenged groups (white bars). N.S., not
significant; N.D., not detected.
Figure 4. Effects of PGD2 on Th1 (IL-2 and IFN- ) and Th2 (IL-4 and
IL-5) cytokine production in BAL fluid. Cytokine levels in BAL fluid were
determined 0, 3 (A), and 24 h (B) after the last challenge on experimental
day 17, as described in Materials and Methods. (A) Data are expressed as
means   SEM per group (n   6). *, P   0.05, between PGD2-pretreated,
low-dose OVA-challenged (black bars) and saline-pretreated, low-dose
OVA-challenged groups (white bars). (B) Gray bars represent the conven-
tional asthma model groups. Data are expressed as means   SEM per
group (n   6). *, P   0.05, between PGD2-pretreated, low-dose OVA-
challenged groups (black bars) and saline-pretreated, low-dose OVA-chal-
lenged groups (white bars) or PGD2-pretreated, saline-challenged groups
(hatched bars). N.S., not significant difference. N.D., not detectable.T
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treated mice showed strong staining for MDC in bronchial
epithelial cells from 3 (Fig. 7 A) to 24 h (not depicted) after
antigen (0.1% OVA) challenge. In the saline-pretreated
mice, however, no MDC was detected after antigen (0.1%
OVA) challenge (Fig. 7 B). When PGD2-pretreated mice
inhaled saline, MDC staining was much less prominent as
compared with that after antigen challenge (Fig. 7 C). No
MDC staining was observed in saline-pretreated, saline-
challenged control mice (Fig. 7 D).
Inhibition of Th2 Cytokine Production and Recruitment of In-
flammatory Cells by Anti-MDC Antibody in PGD2-treated
Mice.  To examine if MDC expressed in the lung had a
functional role in our asthma model, we injected anti-
MDC antibody into the mice just before challenge (Fig. 1,
method 3). As compared with control IgG, anti-MDC an-
tibody significantly inhibited the accumulation of eosino-
phils, lymphocytes, and macrophages in BAL fluid in
PGD2-pretreated mice 24 h after OVA challenge (Fig. 8
A). The levels of IL-4 and IL-5 in BAL fluid were also sig-
nificantly reduced by treatment with anti-MDC antibody
in the PGD2-pretreated mice (Fig. 8 B).
Detection of Pulmonary T1/ST2  T Cells in Sensitized Ani-
mals.  FACS® analysis revealed similar increases in accu-
mulations of total CD3  T cells and T1/ST2  CD3  T
cells in the lungs of all sensitized mice, irrespective of anti-
gen challenge or PGD2 exposure (Fig. 1, method 2; and
Fig. 9 A). In contrast, the percentage of T1/ST2 CD3 
cells (Th2 cells) within CD3  T cells increased sixfold, and
accordingly, the absolute number of T1/ST2 CD3  T
cells increased threefold 24 h after OVA challenge in
PGD2-pretreated mice, as compared with the respective
values in saline-treated mice (Fig. 9 B). The migration of
Th2 cells into the lung was strikingly inhibited by anti-
MDC antibody treatment (Fig. 9 B). These results indicate
that migration of Th2 cells from peripheral vessels to air-
way lumens in response to MDC expressed in bronchial
epithelial cells resulted in increased accumulations of lym-
phocytes, including Th2 cells, and increased Th2 cytokine
production in the lung.
Inhibition of Allergen-induced AHR by Treatment with Anti-
MDC Antibody.  AHR, a prominent pathological alter-
ation in murine models of asthma, was evaluated 24 h after
OVA challenge (Fig. 1, method 3; and Fig. 10). All PGD2-
pretreated, OVA-challenged mice were more sensitive
than saline-pretreated and saline-challenged mice in terms
of AHR induction. However, AHR in PGD2-pretreated,
OVA-challenged mice treated with anti-MDC antibody
was significantly lower than that in control Ig–treated mice.
The rate of change in Penh with increasing doses of meth-
acholine was significantly lower after treatment with anti-
MDC antibody than after treatment with control IgG. This
finding implies that anti-MDC antibody significantly in-
hibited the development of AHR in PGD2-pretreated,
OVA-challenged mice.
Figure 5. Effect of PGD2 on cytokine production by OVA-specific T
cells in vitro. Spleen cells from sensitized and challenged mice were cul-
tured for 24 h with 10 9–10 5 M PGD2 during 10  g/ml OVA stimula-
tion. Data are expressed as means   SEM. These results are representative
of three independent experiments.
Figure 6. Effects of PGD2 on expression of MDC mRNA in vitro.
MDC mRNA was expressed in primary human bronchial epithelial cells in
a dose-dependent manner to 10 9–10 5 M PGD2 after 48-h incubation,
whereas TARC mRNA was constitutively expressed and not influenced by
PGD2. These results are representative of three independent experiments.
Figure 7. Effects of PGD2 on expression of MDC protein in vivo.
Lung sections were obtained from PGD2-pretreated, low-dose OVA-
challenged group after 3 h (A), saline-pretreated, low-dose OVA-chal-
lenged group after 3 h (B), PGD2-pretreated, saline-inhalation group after
3 h (C), and saline-pretreated, saline-inhalation group after 3 h (D). The
sections were stained with polyclonal antibodies against mouse MDC
(original magnification, 200).T
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Discussion
We have described a new mouse model of asthma in
which treatment with exogenous PGD2 was necessary for
the development of marked pulmonary inflammation and
accelerated AHR. This novel model of asthma was specifi-
cally established to analyze the mechanism by which PGD2
contributes to the pathogenesis of asthma. Antigens used for
both sensitization and challenge were carefully titrated, and
the optimal timing of PGD2 pretreatment was examined.
PGD2 is a major prostanoid produced by mast cells;
however, its role in the pathogenesis of asthma has re-
mained unclear. PGD2, its metabolite 15d-PGJ2, or both
can inhibit production of IL-12, a cytokine involved in
Th1 cell differentiation, by macrophages and dendritic cells
(46, 47). Therefore, PGD2 as such or its metabolites may
function to skew the Th2 cell differentiation of naive T
cells (5, 6). However, we observed no effect of PGD2 on
cytokine production by antigen-activated T cells obtained
from the spleen of sensitized mice, indicating that PGD2
did not affect Th2 cytokine production by already-differ-
entiated T cells. Hence, the Th1-inhibiting activity of
PGD2, if any, did not contribute significantly to the PGD2-
induced augmentation of Th2 type inflammation. In addi-
tion, because the numbers of mast cells in pulmonary tissue
were not altered by PGD2 treatment, and PGD2 had no ef-
fect on Th2 cytokine production by BMMCs in vitro (un-
published data), this PGD2-promoted Th2 type inflamma-
tion apparently did not involve mast cells.
Vasodilation and increased vascular permeability are well-
known effects of PGD2. In allergic situations, released PGD2
may facilitate transendothelial migration of inflammatory
cells, such as eosinophils, mast cells, lymphocytes, and
monocytes, possibly via DP receptor–mediated vasodilation-
extravasation (48–51). On the other hand, recent evidence
suggests that PGD2 directly attracts Th2 cells into the lung
(37). In addition, a G protein–coupled, seven-transmem-
brane–type receptor, CRTH2, which is preferentially ex-
pressed in Th2 cells, eosinophils, and basophils (52), has also
been shown to contribute to the PGD2-mediated chemo-
taxis of these cells (53). In this work, we found increased
numbers of eosinophils, lymphocytes, and macrophages in
BAL fluid from PGD2-pretreated, low-dose OVA-chal-
lenged mice in a manner dependent on PGD2 pretreatment.
This Th2-skewed inflammation might result from a direct
chemotactic effect of PGD2 on Th2 cells and eosinophils via
DP receptor, CRTH2 receptor, or both. However, we
found no obvious inflammatory changes or increases in Th2
cytokines after treatment with 10 5 M PGD2 alone, without
antigen challenge. These results suggested that PGD2 by it-
self has no chemotactic activity, but induces chemoattrac-
tants for antigen-activated cells, an idea that clearly supports
the indirect recruitment of Th2 cells by PGD2.
The CCR3 receptor ligand eotaxin is known to act on
Th2 cells, eosinophils, and mast cells (54). In our analysis,
eotaxin was detected in BAL fluid from PGD2-pretreated,
OVA-challenged mice. Nonetheless, eotaxin, a chemokine
produced in response to Th2 cytokines such as IL-4 and -13
(55), was most likely not induced by PGD2 but pro-
duced secondarily in response to massive infiltration of Th2
cells. This assumption is supported by the absence of eo-
taxin in BAL fluid from sensitized mice treated with PGD2
alone. We observed the appearance of OVA-specific T
cells and increased numbers of T1/ST2 CD3  T cells as
Th2 cells in the spleen 12 d after the final intraperitoneal
immunization with OVA (unpublished data). Interestingly,
at this time point T1/ST2 CD3  T cells were also ob-
served in lung tissue, even though the mice had not re-
ceived PGD2 and showed no evidence of inflammation in
the lung. This phenomenon is consistent with the results of
previous papers showing that after immunization memory
T cells are retained in peripheral tissues, including lung
(56–58). Although the number of intrapulmonary T1/
ST2 CD3  cells did not change, even after PGD2 pretreat-
ment and antigen challenge, the number of T1/ST2 
CD3  T cells in BAL fluid increased significantly after
Figure 8. Inhibition of Th2 cytokines and recruitment of inflammatory
cells by anti-MDC antibody in PGD2-treated mice. The numbers of in-
flammatory cells (A) and levels of cytokines (B) in BAL fluid were deter-
mined 24 h after low-dose OVA challenge on experimental day 17, as de-
scribed in Materials and Methods. Saline-pretreated, OVA-challenged
groups are represented by gray bars. Data represent means   SEM per
group (n   5). *, Significant differences (P   0.05) between the PGD2-
pretreated, OVA-challenged control-IgG treatment groups (white bars)
and PGD2-pretreated, OVA-challenged, anti-MDC treatment groups
(black bars).T
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PGD2 pretreatment and antigen challenge. This increase in
T1/ST2 CD3  T cells in BAL fluid was strongly inhibited
by anti-MDC antibody. These results suggest that antigen-
activated Th2 cells, i.e., T1/ST2  CD3  T cells, which
had circulated in pulmonary tissue after sensitization, mi-
grated into the airway lumen in response to MDC induced
locally by PGD2. Because PGD2 alone in naive mice caused
neither tissue inflammatory changes nor Th2 cytokine pro-
duction, antigen-driven activation of T cells or their dis-
tribution (or both) in pulmonary tissue is considered
prerequisite for PGD2-promoted Th2 type pulmonary
inflammation. The identification of MDC as a downstream
mediator of PGD2 in this paper suggests that one of the
roles of antigen-induced T cell activation may be to induce
receptor(s) for chemokine(s).
We found that PGD2 directly induced MDC mRNA,
but not TARC mRNA, in bronchial epithelial cells in
vitro as well as in MDC proteins in vivo in an asthma
model. The fact that MDC protein in epithelium was most
conspicuous in the lung suggested that bronchial epithelial
cell–derived MDC mediates the effect of PGD2 on the in-
filtration of Th2 type cells, leading to the development of
Th2 type inflammation. In fact, neutralization of MDC in
vivo with anti-MDC antibody treatment inhibited not
only the PGD2-promoted transepithelial migration of eo-
sinophils, Th2 cells, and macrophages but also the associated
Th2 cytokine production and AHR. In line with our con-
clusion, the importance of MDC has been pointed out by
Gonzalo et al., who reported that anti-MDC antibody po-
tently inhibits the development of asthma in another mu-
rine model (59). MDC acts on its target cells through
CCR4 (60). Thus, the finding that CCR4 deficiency does
not protect against asthma (61) seems to conflict with our
conclusion. However, CCR4 may not be the sole receptor
for MDC (62). In fact, TARC, a chemokine that also binds
to CCR4, may also serve as a ligand for CCR8 (63), al-
though this remains controversial (64, 65). Perhaps MDC
may also bind to CCR8 or to receptors other than CCR4.
However, works using CCR8 mutant animals or antibod-
ies against TCA-3, a murine high affinity CCR8 ligand, do
not support a role of CCR8 ligands in models of asthma
(66, 67), despite initial expectations (68). One can still ar-
gue that CCR4, its ligands, or both might compensate for
CCR8 and vice versa, a prediction that can only be verified
by studies in mice lacking both CCR4 and CCR8. Perhaps
receptors other than CCR4 and CCR8 transduce MDC
signals. Only further analysis can conclusively resolve these
points of controversy. Apart from the specific receptor for
MDC and its role in asthma, however, our results and
those of Gonzalo et al. (59) clearly indicate a nonredundant
function of MDC in Th2 type pulmonary inflammation
Figure 9. Detection of pulmonary T1/ST2  CD3 
T cells. (A) The numbers of T1/ST2  CD3  T cells
and CD3  T cells in pulmonary tissues were deter-
mined by FACS® analysis 0, 3, and 24 h after low-dose
OVA challenge. White and black bars represent the
nonimmunized groups and immunized groups, respec-
tively. Data represent means   SEM per group (n  
5). *, P   0.05, between nonimmunized groups and
each immunized group. (B) The numbers of T1/ST2 
CD3  T cells and CD3  T cells in BAL fluid were de-
termined 24 h after OVA challenge. Pretreatment with
PGD2 followed by control-IgG treatment and anti-
MDC antibody treatment are shown by white bars and
black bars, respectively. Gray bars represent saline ex-
posure without the antibody. These results are repre-
sentative of three independent experiments.
Figure 10. Inhibition of PGD2 pretreatment and low-dose allergen-
induced AHR by administration of anti-MDC antibody. Mice were first
exposed to nebulized saline, followed by increasing doses (3–25 mg/ml) of
nebulized methacholine for 3 min each. Breathing indices were read for 3
min after each nebulization, and Penh values were determined. AHR was
analyzed 24 h after low-dose OVA challenge in each group. Data repre-
sent means   SEM per group (n   5). *, Significant differences (P   0.05)
between the PGD2-pretreated, OVA-challenged, control-IgG treatment
groups (closed squares) and PGD2-pretreated, OVA-challenged, anti-
MDC treatment groups (closed circles). Saline-pretreated, saline-chal-
lenged, control-IgG treatment groups are represented by open circles.T
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and suggest that MDC may be a therapeutic target for the
management of asthma in humans.
Importantly, our work revealed that MDC serves as a
downstream effector molecule of PGD2 in Th2 type in-
flammation, a previously unknown finding. Identification
of such a molecular link between PGD2 and Th2 recruit-
ment unequivocally demonstrates that PGD2 acts indi-
rectly. Furthermore, this link suggests that the infiltration
of Th2 cells, at least during the early phase of inflamma-
tion, and that of other inflammatory cells occur through
distinct mechanisms. Thus, Th2 cells actively transmigrate
through endothelium in response to PGD2-induced epithe-
lial MDC. The recruited Th2 cells induce other chemo-
kines, such as eotaxin, in situ that attract other inflammatory
cells. Vasodilatation and increased vascular permeability in
response to PGD2 (69) would facilitate both of these
mechanisms. Finally, our results showing that PGD2 has a
role in the induction of MDC but not in that of its related
chemokine TARC suggest that future work should exam-
ine how PGD2 differentially regulates the transcription of
these chemokines. The results of such work may provide
important clues suggesting how regulation of MDC tran-
scription could be used for the treatment of asthma in hu-
mans.
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